Citius Pharmaceuticals, Inc.
CTXR
$0.79
-$0.03-3.76%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 15.84% | 26.24% | 16.87% | -27.77% | -5.82% |
| Total Depreciation and Amortization | 916.42% | 15.46% | -21.59% | 7.49% | 7.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.86% | -4.09% | -22.49% | -28.59% | -30.57% |
| Change in Net Operating Assets | -427.96% | -374.34% | 166.40% | 251.07% | 1,261.24% |
| Cash from Operations | -175.27% | -100.94% | 35.38% | 41.70% | 22.97% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -15.00% | -- | -- | -- |
| Cash from Investing | -- | -15.00% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 711.08% | 18,546.99% | -23.69% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 711.08% | 521.56% | -16.40% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 261.22% | 87.47% | 13.29% | 86.21% | 64.93% |